Gsk Plc (GSK) Return on Investment ROI from the fourth quarter of 2025 to fourth quarter of 2024 and for the year 2025, average high and low, overall ranking from Dec 31 2025 to Dec 31 2024 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Gsk Plc  (NYSE: GSK)


Gsk Plc's ROI from its fourth quarter of 2025 to the fourth quarter of 2024 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Gsk Plc's ROI in the fourth quarter of 2025?
Gsk Plc achieved a return on average invested assets (ROI) of 18.75 % in its fourth quarter of 2025, which is below Gsk Plc's average return on investment, which stands at 80.55%.

ROI has improved compared to 6.87% in the third quarter of 2025, due to net income growth.

Within the Healthcare sector 29 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the third quarter of 2025 from 0 to 108.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Dec 31 2025)
IV. Quarter		 0
III. Quarter		 0
II. Quarter		 0
I. Quarter		 (Dec 31 2024)
IV. Quarter
Y / Y Investment Change TTM 15.29 % -7.62 % 9.19 % 6.49 % 3.71 %
Y / Y Net Income Change TTM 181.14 % -81.11 % -81.11 % -81.11 % -81.11 %
Investment (TTM) in Millions 20,824 52,045 52,045 52,045 15,763
Return On Investment (TTM) 18.75 % 6.87 % 7.12 % 7.39 % 7.69 %
GSK's Overall Ranking # 108 # 0 # # #
Seq. Investment Change TTM 2.94 % 3.7 % 3.84 % 4 % -17.51 %
Seq. Net Income Change TTM 181.14 % 0 % 0 % 0 % -81.11 %
Net Income (TTM) in Millions 8,296 2,951 2,951 2,951 2,951

GSK Company Profile >> Back to GSK Roi Comparisons >> See Annual GSK Return On Investment



Return On Investment GSK's Ranking
Within: No.
Industry # 11
Sector # 30
Overall # 108

Return On Investment Statistics
High Average Low
269.47 %
80.55 %
32.25 %
(Dec 31 2022)   (Dec 31 2024)







Financial Statements
Gsk Plc's IV. Quarter Investments $ 20,824 Millions GSK's Balance sheet
Gsk Plc's IV. Quarter Income $ 8,296 Millions Quarterly GSK's Income Statement
GSK's Income by Division See GSK's Income by Division


GSK Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 20,824 15,763 48,343 11,643 73,591
Y / Y Investment Growth 32.11 % -67.39 % 315.21 % -84.18 % -6.29 %
Net Income in Millions 8,296 3,772 6,603 19,325 7,014
Y / Y Net Income Growth 119.96 % -42.88 % -65.83 % 175.52 % -14.41 %
Annual Return On Investment 39.84 % 23.93 % 13.66 % 165.98 % 9.53 %


Annual Roi Comment
In the fiscal year 2025 ROI improved to 39.84 % compared to the prior year, due to net income growth.

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
GSK's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for GSK's Competitors
Subscribers only: Roi for Gsk Plc's Suppliers
Subscribers only: Return On Investment for GSK's Customers

Other Ratios
GSK's Roa GSK's Inventory Turnover Ratio GSK's Growth Rates GSK's Dividend Statistics
GSK's Profitability Ratios GSK's Asset Turnover Ratio GSK's Dividend Growth
GSK's Roe GSK's Valuation Ratios GSK's Financial Strength Ratios GSK's Dividend Payout Ratio



Companies with similar Return On Investment at Dec 31 2025, within Healthcare Sector ROI
Q32 Bio Inc   50.33 %
Idexx Laboratories Inc  48.69 %
Theravance Biopharma inc   46.03 %
Elite Pharmaceuticals Inc   45.80 %
Enlivex Therapeutics Ltd  45.75 %
Gsk Plc  44.94 %
Galmed Pharmaceuticals Ltd   43.72 %
Abeona Therapeutics Inc   42.25 %
Alpha Tau Medical Ltd  42.04 %
Dariohealth Corp   41.31 %
Acadia Pharmaceuticals Inc   39.64 %
Medinotec Inc   37.45 %
Zevra Therapeutics Inc   36.78 %
Oramed Pharmaceuticals Inc  35.86 %
Ptc Therapeutics inc   35.12 %
Mettler toledo International Inc   34.74 %
Newgenivf Group Limited  32.05 %
Eli Lilly And Company  31.62 %
Indivior Pharmaceuticals Inc   31.00 %
Hutchmed china Limited  30.87 %
Medpace Holdings Inc   30.44 %
Adma Biologics Inc   28.75 %
Carlisle Companies Incorporated  27.24 %
Incyte Corporation  27.08 %
Vaxart Inc   26.63 %
Compugen Ltd  26.32 %
Arrowhead Pharmaceuticals Inc   25.56 %
Puma Biotechnology Inc   25.39 %
Catalyst Pharmaceuticals Inc   24.25 %
Iradimed Corporation  22.97 %

Date modified: 2026-09-09T12:36:18+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.